Immunome, Inc.
IMNM
$7.17
-$0.23-3.11%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -35.50% | -0.62% | 62.73% | 436.51% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -35.50% | -0.62% | 62.73% | 436.51% | -- |
| Cost of Revenue | 461.06% | 416.78% | 204.05% | 87.67% | 2.48% |
| Gross Profit | -1,228.42% | -986.04% | -279.45% | -36.27% | 59.74% |
| SG&A Expenses | 67.65% | 101.10% | 79.55% | 76.62% | 44.86% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 280.15% | 270.82% | 150.99% | 83.12% | 18.41% |
| Operating Income | -434.17% | -392.89% | -173.01% | -54.24% | 20.42% |
| Income Before Tax | -174.29% | -1,290.60% | -904.33% | -686.19% | -189.48% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -174.29% | -1,290.60% | -904.33% | -686.19% | -189.48% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -174.29% | -1,290.60% | -904.33% | -686.19% | -189.48% |
| EBIT | -434.17% | -392.89% | -173.01% | -54.24% | 20.42% |
| EBITDA | -437.26% | -396.07% | -173.41% | -54.60% | 20.76% |
| EPS Basic | -55.52% | -235.99% | -155.82% | -121.02% | -7.53% |
| Normalized Basic EPS | -63.35% | 1.06% | 31.68% | 39.63% | 51.67% |
| EPS Diluted | -55.64% | -235.64% | -155.60% | -120.49% | -7.32% |
| Normalized Diluted EPS | -63.35% | 1.06% | 31.68% | 39.63% | 51.67% |
| Average Basic Shares Outstanding | 195.47% | 340.31% | 242.29% | 144.48% | 63.64% |
| Average Diluted Shares Outstanding | 195.47% | 340.31% | 242.29% | 144.48% | 63.64% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |